Paper
0
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Authors
Milton Packer,Stefan Anker
Javed Butler,Gerasimos Filippatos,Stuart Pocock,Peter Carson,James Januzzi,Subodh Verma,Hiroyuki Tsutsui,Martina Brueckmann,Waheed Jamal,Karen Kimura,Janet Schnee,Cordula Zeller,Daniel Cotton,Edimar Bocchi,Michael Böhm,Dong‐Ju Choi,Vijay Chopra,Eduardo Chuquiure‐Valenzuela,Nadia Giannetti,Stefan Janssens,Jian Zhang,José González‐Juanatey,Sanjay Kaul,Hans‐Peter Rocca,Béla Merkely,Stephen Nicholls,Sergio Perrone,Ileana Piña,Piotr Ponikowski,Naveed Sattar,Michel Galinier,Marie-France Séronde,Jindřich Špinar,Iain Squire,Stefano Taddei,Christoph Wanner,Faı̈ez Zannad
+37 authors
,Michele SenniPublished
Aug 28, 2020
Show more
Save
Tip0
TipSave
Abstract
Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes. More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart failure, including those with a markedly reduced ejection fraction.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.